{"entity":{"id":"nct07175389","kind":"trial","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","aka":[],"tldr":"A phase 1/2 trial of serplulimab in pancreatic cancer, run by West China Hospital, not yet recruiting.","summary":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure is a phase 1/2, interventional study registered as NCT07175389 by West China Hospital, with a registry enrolment figure of 10 participants, started 2026-09-01 and due to reach its primary completion in 2028-09-01. Interventions recorded: JDB153; Serplulimab. Conditions listed: Refractory Pancreatic Ductal Adenocarcinoma; Refractory Pancreatic Adenocarcinoma. Primary outcome: Incidence of Treatment-Related Adverse Events; Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"* 1\\) Histologically or cytologically confirmed diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer; 2) Age 18-75 years, inclusive; no sex restrictions; 3) Life expectancy ≥12 weeks; 4) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; 5) Documented dis\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07175389","url":"https://clinicaltrials.gov/study/NCT07175389"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["serplulimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07175389","phase":"1/2","setting":"A Phase Ib/II Clinical Trial of JDB153 Combined With Serplulimab for the Treatment of Pancreatic Cancer Refractory to Standard Therapy","sponsor":"West China Hospital","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07175389/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}